Search Result

Results for "

HSP90+inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Payload (3) Akt (4) Androgen Receptor (1) Antibiotic (6) APC (1) Apoptosis (23) ATP-binding cassette (ABC) transporters (1) Autophagy (9) Bacterial (6) Bcr-Abl (2) c-Kit (1) c-Myc (2) Caspase (1) CDK (7) Cytochrome P450 (1) DNA/RNA Synthesis (1) Drug Intermediate (1) Drug Metabolite (2) EGFR (1) Epigenetic Reader Domain (1) ERK (2) Fungal (4) HDAC (1) HIV (1) HSP (93) Influenza Virus (2) Isotope-Labeled Compounds (1) JNK (1) MHC (1) Mitophagy (3) Necroptosis (1) NF-κB (2) p38 MAPK (2) Parasite (1) PDGFR (1) PROTACs (1) Raf (2) Reference Standards (6) RIP kinase (1) STAT (2) β-catenin (1)
By Research Areas:	Cancer (87) Cardiovascular Disease (1) Infection (18) Inflammation/Immunology (9) Metabolic Disease (2) Neurological Disease (4)

By Targets:

ADC Payload (3)

Akt (4)

Androgen Receptor (1)

Antibiotic (6)

APC (1)

Apoptosis (23)

ATP-binding cassette (ABC) transporters (1)

Autophagy (9)

Bacterial (6)

Bcr-Abl (2)

c-Kit (1)

c-Myc (2)

Caspase (1)

CDK (7)

Cytochrome P450 (1)

DNA/RNA Synthesis (1)

Drug Intermediate (1)

Drug Metabolite (2)

EGFR (1)

Epigenetic Reader Domain (1)

ERK (2)

Fungal (4)

HDAC (1)

HIV (1)

HSP (93)

Influenza Virus (2)

Isotope-Labeled Compounds (1)

JNK (1)

MHC (1)

Mitophagy (3)

Necroptosis (1)

NF-κB (2)

p38 MAPK (2)

Parasite (1)

PDGFR (1)

PROTACs (1)

Raf (2)

Reference Standards (6)

RIP kinase (1)

STAT (2)

β-catenin (1)

By Research Areas:

Cancer (87)

Cardiovascular Disease (1)

Infection (18)

Inflammation/Immunology (9)

Metabolic Disease (2)

Neurological Disease (4)

Inhibitors & Agonists

Fluorescent Dyes

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10211

Tanespimycin Maximum Cited Publications 69 Publications Verification 17-AAG; NSC 330507; CP 127374	HSP Autophagy Mitophagy Bacterial Apoptosis Antibiotic	Infection Cancer
Tanespimycin (17-AAG) is a potent *HSP90* inhibitor with an IC₅₀ of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90 . Tanespimycin depletes cellular STK38/NDR1 and reduces STK38 kinase activity. Tanespimycin also downregulates the stk38 gene expression .

HY-15230

Geldanamycin Maximum Cited Publications 40 Publications Verification	HSP Bacterial Influenza Virus Antibiotic	Infection Inflammation/Immunology Cancer
Geldanamycin is a *Hsp90* inhibitor with antimicrobial activity against many Gram-positive and some Gram-negative bacteria. Geldanamycin has anti-influenza virus H5N1 activities.

HY-15205

Ganetespib 40+ Cited Publications STA-9090	HSP Apoptosis	Cancer
Ganetespib (STA-9090) is a heat shock protein 90 (HSP90) inhibitor which exhibits potent cytotoxicity in a wide variety of hematological and solid tumor cell lines. Ganetespib has antiangiogenic effects in colorectal cancer mediated through inhibition of HIF-1α and STAT3 .

HY-102007A

Gamitrinib TPP hexafluorophosphate 10+ Cited Publications	HSP	Cancer
Gamitrinib TPP hexafluorophosphate is a Gamitrinib (GA) mitochondrial matrix inhibitor. Gamitrinib TPP hexafluorophosphate is a mitochondrial targeted *HSP90* inhibitor with anti-cancer activity.

HY-10215

Luminespib 20+ Cited Publications VER-52296; AUY922; NVP-AUY922	HSP Autophagy Apoptosis	Cancer
Luminespib (VER-52296) is a potent *HSP90* inhibitor with IC₅₀s of 7.8 and 21 nM for HSP90α and HSP90β, respectively .

HY-11038

Zelavespib 10+ Cited Publications PU-H71	HSP	Cancer
Zelavespib (PU-H71) is a potent *Hsp90* inhibitor, with an IC₅₀ of 51 nM in MDA-MB-468 cells.

HY-15190

NVP-HSP990 4 Publications Verification HSP-990	HSP Apoptosis	Cancer
NVP-HSP990 is a potent, selective and orally active *Hsp90* inhibitor, with IC₅₀ values of 0.6, 0.8, and 8.5 nM for Hsp90α, Hsp90β, and Grp94, respectively.

HY-14463

Onalespib 10+ Cited Publications AT13387	HSP	Cancer
Onalespib (AT13387) is a potent and cross the blood-brain barrier **heat-shock-protein-90 (Hsp90)** inhibitor. Onalespib inhibits the proliferation, survival and migration. Onalespib decreases the expression of EGFR, p-EGFR, AKT, P-AKT, ERK1/2, P-ERK1/2, S6, P-S6 protein. Onalespib shows antitumor activity. Onalespib has the potential for the research of non-small cell lung cancer (NSCLC) .

HY-13469

Debio 0932 5+ Cited Publications CUDC-305	HSP	Cancer
Debio 0932 (CUDC-305) is an orally active *HSP90* inhibitor, with IC₅₀s of 100 and 103 nM for HSP90α and HSP90β, respectively .

HY-13313

XL888 5 Publications Verification	HSP Apoptosis	Cancer
XL888 is a potent and orally active *HSP90* inhibitor with an IC₅₀ value of 24 nM. XL888 shows anti-proliferation activity and induces Apoptosis. XL888 shows anti-tumor activity .

HY-10214

SNX-2112 3 Publications Verification PF-04928473	HSP Autophagy	Cancer
SNX-2112 (PF 04928473) is an orally active *Hsp90* inhibitor, with a K_d of 16 nM for *Hsp90* and IC₅₀s of 30 nM, 30 nM for Hsp90 α and Hsp90 β, also induces Her-2 degradation, and inhibits Grp94 and Trap-1, with IC₅₀s of 10 nM, 4.275 μM and 0.862 μM, respectively . SNX-2112 (PF 04928473) binds Hsp90 isoforms Hsp90α, Hsp90β and Hsp90b1/Grp94 with K_ds of 4 nM, 6 nM and 484 nM, respectively .

HY-10213

SNX-5422 1 Publications Verification PF-04929113	HSP	Cancer
SNX-5422 (PF-04929113), a prodrug of SNX-2112, is an orally active *Hsp90* inhibitor, with a K_d of 41 nM, and also induces Her-2 degradation, with an IC₅₀ of 37 nM.

HY-107577

Gedunin	HSP	Infection Inflammation/Immunology Cancer
Gedunin is a limonoid with anti-cancer, anti-viral, anti-inflammatory and insecticidal activities. Gedunin acts as a potent *Hsp90* inhibitor and induces the degradation of Hsp90-dependent client proteins. Geduni may obstructs the entry of SARS-CoV-2 virus into human host cells and can be used for COVID-19 research .

HY-13468

KW-2478 4 Publications Verification	HSP Apoptosis Bcr-Abl p38 MAPK CDK STAT	Cancer
KW-2478 is an *HSP90* inhibitor (IC₅₀ = 3.8 nM). KW-2478 inhibits the growth and induces apoptosis in chronic myeloid leukemia (CML) cells and liver cancer cells. KW-2478 weakens the BCR/ABL and MAPK signaling pathways, leading to increased p27 and p21 expression and decreased cyclin B1 expression. KW-2478 downregulates STAT3 expression. KW-2478 may be used in research on cancers such as CML and liver cancer .

HY-15986

VER-49009 CCT 129397	HSP	Cancer
VER-49009 is a *Hsp90* inhibitor, with an IC₅₀ of 25 nM and a K_d of 78 nM.

HY-15984

VER-50589 1 Publications Verification	HSP Apoptosis	Cancer
VER-50589 is a *Hsp90* inhibitor, with an IC₅₀ of 21 nM and a K_d of 4.5 nM.

HY-130851

HS-27	HSP	Cancer
HS-27, a fluorescently-tethered *Hsp90* inhibitor, assays surface Hsp90 expression on intact tissue specimens. HS-27 is made up of the core elements of SNX-5422, an Hsp90 inhibitor, tethered via a PEG linker to a fluorescein derivative (fluorescein isothiocyanate or FITC), that binds to ectopically expressed Hsp90. HS-27 has potential use in a see-and-treat paradigm in breast cancer .

HY-10942

VER-82576 5 Publications Verification NVP-BEP800	HSP	Cancer
VER-82576 (NVP-BEP800) is a potent, orally available and selective *Hsp90* inhibitor, with an IC₅₀ of 58 nM for Hsp90β; VER-82576 also slightly blocks Grp94 and Trap-1, with IC₅₀s of 4.1 and 5.5 μM, respectively.

HY-102007

Gamitrinib TPP	HSP	Cancer
Gamitrinib TPP is a Gamitrinib (GA) mitochondrial matrix inhibitor. Gamitrinib TPP is a mitochondrial targeted *HSP90* inhibitor with anti-cancer activity.

HY-N1455

Falcarinol 1 Publications Verification Panaxynol; Carotatoxin	HSP Apoptosis	Cancer
Falcarinol (Panaxynol) is a natural, orally active *Hsp90* inhibitor targeting both the N-terminal and C-terminal of Hsp90 with limited toxicities. Falcarinol (Panaxynol) induces apoptosis . Falcarinol is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-W010649

Isoxazole	HSP Epigenetic Reader Domain ATP-binding cassette (ABC) transporters Bacterial Fungal Antibiotic	Infection Metabolic Disease Inflammation/Immunology Cancer
Isoxazole is a member of the five-membered heterocycle drug scaffold. Isoxazole has been used as a BET bromodomain inhibitor and can improve β-cell function in a diabetic mouse model. Isoxazole and its derivatives exhibit broad biological activities (such as antimicrobial, antibacterial, antifungal, antiviral, anticancer, anti-inflammatory, immunomodulatory, analgesic, anti-tuberculosis, and anti-diabetic effects). For example, the bicyclic Isoxazole can act as an *HSP90* inhibitor, and the tricyclic Isoxazole is promising as a selective multidrug resistance protein (MRP1) inhibitor .

HY-148215A

Hsp90-IN-17 hydrochloride	HSP	Neurological Disease Cancer
Hsp90-IN-17 (Example 5) hydrochloride is an *HSP90* inhibitor that can be used in the study of proliferative diseases, such as cancer and neurodegenerative diseases .

HY-133705

Geldanamycin-FITC 1 Publications Verification	HSP	Others
Geldanamycin-FITC, a Geldanamycin fluorescent probe, can be used in a fluorescence polarization assay for HSP90 inhibitors. Geldanamycin-FITC also can be used for detection of cell surface HSP90 (Ex/Em = 488/515 nm) .

HY-W013675

2-Methoxyhydroquinone	HSP	Inflammation/Immunology
2-Methoxyhydroquinone is a phenolic compound that reduces TNF-α-induced production of chemokine (C-C motif) ligand 2 (CCL2) with an IC₅₀ value of 64.3 µM. 2-Methoxyhydroquinone is also a precursor in the synthesis of the Hsp90 inhibitor Geldanamycin (HY-15230) .

HY-119046

SNX-0723 2 Publications Verification	HSP Parasite	Infection
SNX-0723 is a potent *Hsp90* Inhibitor with anti-Plasmodium activity. SNX-0723 shows high binding affinity for HsHsp90 and PfHsp90 with K_is of 4.4 and 47 nM, respectively. SNX-0723 inhibits liver-stage P. berghei ANKA parasites with the EC₅₀ of 3.3 μM .

HY-119906

Conglobatin FW-04-806	HSP Apoptosis	Cancer
Conglobatin (FW-04-806), a macrolide dilactone, is isolated from the culture of Streptomyces conglobatus. Conglobatin is an orally active *Hsp90* inhibitor. Conglobatin can bind to the N-terminal domain of Hsp90 and disrupt Hsp90-Cdc37 complex formation. Conglobatin induces apoptosis in human breast cancer cells and esophageal squamous cell carcinoma cells, and exhibits antitumor activity in vivo .

HY-100555

CH5138303	HSP	Infection Cancer
CH5138303 is a potent and orally active *Hsp90* inhibitor. CH5138303 shows high binding affinity for N-terminal *Hsp90α, with K_d* of 0.52 nM. CH5138303 shows potent anti-proliferative activity against human cancer cell lines (HCT116 and NCI-N87), with IC₅₀ values of 0.098 and 0.066 μM, respectively. CH5138303 shows high oral bioavailability in mice (F=44.0%). CH5138303 shows potent antitumor efficacy in a human NCI-N87 gastric cancer xenograft model .

HY-11038B

Zelavespib hydrochloride 10+ Cited Publications PU-H71 hydrochloride	HSP	Cancer
Zelavespib (PU-H71) hydrochloride is a potent *Hsp90* inhibitor, with an IC₅₀ of 51 nM in MDA-MB-468 cells.

HY-11038D

Zelavespib formic 10+ Cited Publications PU-H71 formic	HSP	Cancer
Zelavespib formic (PU-H71 formic) is a potent *Hsp90* inhibitor with an IC₅₀ value of 51 nM for *Hsp90* in MDA-MB-468 cells .

HY-132995

DP-1	Drug Metabolite	Others
DP-1, a degradation product of SDC-TRAP-0063, is a fragment of Ganetespib. Ganetespib is a heat shock protein 90 (HSP90) inhibitor with anti-tumor activity .

HY-W107935

Hsp90-IN-37	HSP	Cancer
Hsp90-IN-37 (Z-2) is a heat shock protein 90 (Hsp90) inhibitor that inhibits Hsp90 enzymatic activity by 69%. Hsp90-IN-37 has antitumor activity .

HY-153588

HSP90-IN-22	HSP	Cancer
HSP90-IN-22 (Compound 35) is an Hsp90 inhibitor with antiproliferative properties on cells with IC₅₀ values of 3.65 μM for MCF7 breast cancer cells and 2.71 μM for SKBr3 breast cancer cells, respectively.

HY-N3417

Kongensin A 1 Publications Verification	HSP RIP kinase Apoptosis Necroptosis	Inflammation/Immunology Cancer
Kongensin A is a natural product isolated from Croton kongensis. Kongensin A is an effective, covalent *HSP90* inhibitor that blocks RIP3-dependent necroptosishas. Kongensin A is a potent necroptosis inhibitor and an apoptosis inducer. Kongensin A has potential anti-necroptosis and anti-inflammation applications .

HY-162589

Lw13	PROTACs HSP Apoptosis	Cancer
Lw13 is a *Hsp90*-targeting PROTAC and achieves maximum degradation at a concentration of 0.05 μM in Siha cells. Lw13 induces cell apoptosis and exhibits potent anti-tumor activity both in vitro and in vivo(Sturcture Note:(Blue: Cereblon ligand (HY-A0003), Black: linker；Pink: Hsp90 inhibitor SNX-5422 (HY-10213)) .

HY-10211R

Tanespimycin (Standard) 17-AAG (Standard); NSC 330507 (Standard); CP 127374 (Standard)	Reference Standards HSP Autophagy Mitophagy Bacterial Apoptosis Antibiotic	Infection Cancer
Tanespimycin (Standard) is the analytical standard of Tanespimycin. This product is intended for research and analytical applications. Tanespimycin (17-AAG) is a potent *HSP90* inhibitor with an IC₅₀ of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90 . Tanespimycin depletes cellular STK38/NDR1 and reduces STK38 kinase activity. Tanespimycin also downregulates the stk38 gene expression .

HY-113916

Onalespib lactate AT13387 lactate	HSP	Cancer
Onalespib lactate is a potent and cross the blood-brain barrier **heat-shock-protein-90 (Hsp90)** inhibitor with an K_d value of 0.71 nM. Onalespib lactate inhibits the proliferation, survival and migration. Onalespib lactate decreases the expression of EGFR, p-EGFR, AKT, P-AKT, ERK1/2, P-ERK1/2, S6, P-S6 protein. Onalespib lactate shows antitumor activity. Onalespib lactate has the potential for the research of non-small cell lung cancer (NSCLC) .

HY-164399

SST0116CL1	HSP EGFR CDK Akt	Cancer
SST0116CL1 is a *HSP90* inhibitor (IC₅₀: 0.21 μM). SST0116CL1 binds to the ATP binding pocket of Hsp90, and interferes with Hsp90 chaperone function thus resulting in client protein (EGFR, CDK4 and AKT) degradation. SST0116CL1 induces degradation of Her2 in BT-474 cell (IC₅₀: 0.2 μM). SST0116CL1 has antiproliferative activity and inhibits tumor growth. SST0116CL1 can be used for the study of leukemia, gastric and ovarian carcinoma .

HY-176279

Hsp90-IN-42	HSP	Cancer
Hsp90-IN-42 (Compound 13l) is a potent heat shock protein 90 (Hsp90) inhibitor (IC₅₀=15.65 nM). Hsp90-IN-42 reduces the stability of the epidermal growth factor receptor (EGFR), suppressing the activation of the EGFR-Akt signaling pathway, inducing G0/G1 phase arrest in colorectal cancer cells (such as HT-29 cells), and slightly triggering apoptosis. Hsp90-IN-42 also inhibits cell proliferation and migration by down-regulating the expression of CDK12, CDK13, and Bcl-2 proteins, and up-regulating the expression of Bax protein. Hsp90-IN-42 is promising for research of colorectal cancer .

HY-133571

Aminohexylgeldanamycin AHGDM	HSP ADC Payload	Cancer
Aminohexylgeldanamycin (AHGDM), a Geldanamycin derivative, is a potent *HSP90* inhibitor. Aminohexylgeldanamycin shows antiangiogenic and antitumor activities .

HY-108248

KU-32	HSP	Cardiovascular Disease Neurological Disease Metabolic Disease
KU-32 is a novel, novobiocin-based *Hsp90* inhibitor that can protect against neuronal cell death.

HY-174476

HSP90i	HSP Drug Intermediate	Cancer
HSP90i is a *HSP90* inhibitor. HSP90i can be used as a drug intermediate to synthesize LYTACs, such as dPDL1-4 (HY-174468) .

HY-122878

HS-131	HSP	Cancer
HS-131, a near infrared dye tethered *Hsp90* inhibitor, is able to detect oncogene-driven breast cancers, including multiple different molecular subtypes of human breast cancers .

HY-15230R

Geldanamycin (Standard)	Reference Standards HSP Bacterial Influenza Virus Antibiotic	Infection Inflammation/Immunology Cancer
Geldanamycin (Standard) is the analytical standard of Geldanamycin. This product is intended for research and analytical applications. Geldanamycin is a *Hsp90* inhibitor with antimicrobial activity against many Gram-positive and some Gram-negative bacteria. Geldanamycin has anti-influenza virus H5N1 activities.

HY-13468A

KW-2478 hydrochloride	HSP Apoptosis Bcr-Abl p38 MAPK CDK STAT	Cancer
KW-2478 hydrochloride is an *HSP90* inhibitor (IC₅₀ = 3.8 nM). KW-2478 hydrochloride inhibits the growth and induces apoptosis in chronic myeloid leukemia (CML) cells and liver cancer cells. KW-2478 hydrochloride weakens the BCR/ABL and MAPK signaling pathways, leading to increased p27 and p21 expression and decreased cyclin B1 expression. KW-2478 hydrochloride downregulates STAT3 expression. KW-2478 hydrochloride may be used in research on cancers such as CML and liver cancer .

HY-147125

DDO-6600	HSP Akt CDK Raf Apoptosis	Cancer
DDO-6600 is a covalent *Hsp90* inhibitor. DDO-6600 disrupts the interaction between Hsp90 and its co-chaperone protein Cdc37, thereby inducing the degradation of kinase client proteins (such as AKT, CDK4, c-Raf). DDO-6600 has inhibitory activity against various cancer cells. DDO-6600 inhibits the migration and invasion of HCT-116 cells, and induces cell cycle arrest and apoptosis. DDO-6600 significantly inhibits tumor growth in the HCT-116 xenograft tumor model. DDO-6600 can be used for research on colorectal cancer .

HY-133571A

Aminohexylgeldanamycin hydrochloride AHGDM hydrochloride	HSP ADC Payload	Cancer
Aminohexylgeldanamycin (AHGDM) hydrochloride, a Geldanamycin derivative, is a potent *HSP90* inhibitor. Aminohexylgeldanamycin hydrochloride shows antiangiogenic and antitumor activities .

HY-148215

Hsp90-IN-17	HSP	Cancer
Hsp90-IN-17 (Example 5) is an *HSP90* inhibitor that can be used in the study of proliferative diseases, such as cancer and neurodegenerative diseases .

HY-162365

JD-02	HSP Apoptosis Autophagy	Cancer
JD-02 is a novel *Hsp90* inhibitor. JD-02 can induce autophagy and apoptosis. JD-02 increses the level of reactive oxygen species .

HY-10213A

SNX-5422 mesylate PF-04929113 mesylate	HSP	Cancer
SNX-5422 Mesylate (PF-04929113 Mesylate), a prodrug of SNX-2112, is an orally active *Hsp90* inhibitor, with a K_d of 41 nM, and also induces Her-2 degradation, with an IC₅₀ of 37 nM.

HY-148963

HSP90-IN-20	HSP	Cancer
HSP90-IN-20 (compound 78p) is a potent *HSP90* inhibitor with an IC₅₀ of ≤10 μM. HSP90-IN-20 has the potential for cancers research .

Cat. No.	Product Name	Type

HY-133705

Geldanamycin-FITC 1 Publications Verification	Fluorescent Dyes
Geldanamycin-FITC, a Geldanamycin fluorescent probe, can be used in a fluorescence polarization assay for HSP90 inhibitors. Geldanamycin-FITC also can be used for detection of cell surface HSP90 (Ex/Em = 488/515 nm) .

HY-122878

HS-131	Fluorescent Dyes
HS-131, a near infrared dye tethered *Hsp90* inhibitor, is able to detect oncogene-driven breast cancers, including multiple different molecular subtypes of human breast cancers .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-15230

Geldanamycin Maximum Cited Publications 40 Publications Verification	Infection Quinones Structural Classification Microorganisms Classification of Application Fields Benzene Quinones Inflammation/Immunology Disease Research Fields Source Classification	HSP Bacterial Influenza Virus Antibiotic
Geldanamycin is a *Hsp90* inhibitor with antimicrobial activity against many Gram-positive and some Gram-negative bacteria. Geldanamycin has anti-influenza virus H5N1 activities.

HY-107577

Gedunin	Infection Triterpenes other families Classification of Application Fields Terpenoids Plants Inflammation/Immunology Disease Research Fields Source Classification	HSP
Gedunin is a limonoid with anti-cancer, anti-viral, anti-inflammatory and insecticidal activities. Gedunin acts as a potent *Hsp90* inhibitor and induces the degradation of Hsp90-dependent client proteins. Geduni may obstructs the entry of SARS-CoV-2 virus into human host cells and can be used for COVID-19 research .

HY-N1455

Falcarinol 1 Publications Verification Panaxynol; Carotatoxin	Natural Products Classification of Application Fields Ambrosia psilostachya DC. Umbelliferae Plants Disease Research Fields Source Classification Cancer	HSP Apoptosis
Falcarinol (Panaxynol) is a natural, orally active *Hsp90* inhibitor targeting both the N-terminal and C-terminal of Hsp90 with limited toxicities. Falcarinol (Panaxynol) induces apoptosis . Falcarinol is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-119906

Conglobatin FW-04-806	Natural Products Microorganisms Classification of Application Fields Disease Research Fields Cancer Source Classification	HSP Apoptosis
Conglobatin (FW-04-806), a macrolide dilactone, is isolated from the culture of Streptomyces conglobatus. Conglobatin is an orally active *Hsp90* inhibitor. Conglobatin can bind to the N-terminal domain of Hsp90 and disrupt Hsp90-Cdc37 complex formation. Conglobatin induces apoptosis in human breast cancer cells and esophageal squamous cell carcinoma cells, and exhibits antitumor activity in vivo .

HY-N3417

Kongensin A 1 Publications Verification	Classification of Application Fields Euphorbiaceae Plants Inflammation/Immunology Disease Research Fields Croton kongensis Gagnep.	HSP RIP kinase Apoptosis Necroptosis
Kongensin A is a natural product isolated from Croton kongensis. Kongensin A is an effective, covalent *HSP90* inhibitor that blocks RIP3-dependent necroptosishas. Kongensin A is a potent necroptosis inhibitor and an apoptosis inducer. Kongensin A has potential anti-necroptosis and anti-inflammation applications .

HY-15230R

Geldanamycin (Standard)	Quinones Structural Classification Microorganisms Benzene Quinones Source Classification	Reference Standards HSP Bacterial Influenza Virus Antibiotic
Geldanamycin (Standard) is the analytical standard of Geldanamycin. This product is intended for research and analytical applications. Geldanamycin is a *Hsp90* inhibitor with antimicrobial activity against many Gram-positive and some Gram-negative bacteria. Geldanamycin has anti-influenza virus H5N1 activities.

Cat. No.	Product Name	Chemical Structure

HY-10211S

Tanespimycin-d5

Tanespimycin-d₅ (17-AAG-d₅; NSC 330507-d₅; CP 127374-d₅) is the deuterium labeled Tanespimycin (HY-10211). Tanespimycin (17-AAG) is a potent HSP90 inhibitor with an IC₅₀ of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90 . Tanespimycin depletes cellular STK38/NDR1 and reduces STK38 kinase activity. Tanespimycin also downregulates the stk38 gene expression .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks